Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.38 |
| ▸ | ACE | P12821 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | YAP1 | P46937 | 1/20 | 0.33 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL647621 | 1.00 | DPP4 (0.38) | DPP4ACEALDH1A1DPP8YAP1 | |
| SCHEMBL6202997 | 1.00 | DPP4 (0.38) | DPP4ACEALDH1A1DPP8YAP1 | |
| SCHEMBL647869 | 0.85 | DPP4 (0.38) | DPP4ALDH1A1DPP8 | |
| SCHEMBL4704107 | 0.85 | DPP4 (0.38) | DPP4ALDH1A1DPP8 | |
| SCHEMBL14263094 | 0.83 | DPP4 (0.41) | DPP4ACEALDH1A1DPP8 | |
| SCHEMBL14263088 | 0.81 | DPP4 (0.35) | DPP4DPP8 | |
| SCHEMBL645766 | 0.81 | DPP4 (0.41) | DPP4ACEALDH1A1 | |
| SCHEMBL6204432 | 0.81 | DPP4 (0.41) | DPP4ACEALDH1A1 | |
| SCHEMBL25305608 | 0.80 | DPP4 (0.37) | DPP4ACEALDH1A1DPP8 | |
| SCHEMBL4983693 | 0.78 | DPP4 (0.60) | DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152600-A1 | SYNTHESIS OF (2S,5R)-5-ETHYNYL-1-PYRROLIDINE-2-CARBONITRILE | ABBVIE INC (US) | 2016-06-02 | — | — | US | disclosed |
| US-9260411-B2 | Synthesis of (2S,5R)-5-ethynyl-1-{N-(4-methyl-1-(4-carboxy-pyridin-2-yl)piperidin-4-yl)glycyl}pyrrolidine-2-carbonitrile | ABBVIE INC. (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2535338-A1 | Synthesis of (2S,5R)-5-ethynyl-1-{N-(4-methyl-1-(4-carboxy-pyridin-2-yl)piperidin-4-yl)glycyl}pyrrolidine-2-carbonitrile | Abbott Laboratories (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20080058528-A1 | useful in the treatment of disorders mediated by DPP-IV such as, but not limited to, diabetes, type II diabetes, hyperglycemia, Syndrome X, hyperinsulinemia and obesity | ABBVIE INC. | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152600-A1 | SYNTHESIS OF (2S,5R)-5-ETHYNYL-1-PYRROLIDINE-2-CARBONITRILE | PNN, PARN, AZI2 | DPP4 1253/4885ACE 3751/4885ALDH1A1 638/4885 |
| US-20080058528-A1 | useful in the treatment of disorders mediated by DPP-IV such as, but not limited to, diabetes, type II diabetes, hyperglycemia, Syndrome X, hyperinsulinemia and obesity | DPP4, DPP7, DPP3 | DPP4 1/4885ACE 486/4885ALDH1A1 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.